Cantor Fitzgerald Weighs in on Innoviva FY2026 Earnings

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Innoviva in a report issued on Friday, July 11th. Cantor Fitzgerald analyst S. Seedhouse expects that the biotechnology company will post earnings of $1.84 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $26.00 target price on the stock. The consensus estimate for Innoviva's current full-year earnings is $0.33 per share.

INVA has been the subject of a number of other research reports. HC Wainwright began coverage on Innoviva in a research report on Monday. They set a "buy" rating and a $40.00 price target for the company. Wall Street Zen raised Innoviva from a "hold" rating to a "buy" rating in a research note on Wednesday, April 30th.

Innoviva Stock Performance

INVA stock traded up $0.26 during trading on Monday, reaching $20.22. 451,200 shares of the company's stock were exchanged, compared to its average volume of 711,161. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 0.40. Innoviva has a 1-year low of $16.67 and a 1-year high of $22.00. The company's fifty day moving average price is $19.84 and its 200-day moving average price is $18.61. The firm has a market cap of $1.27 billion, a PE ratio of -20.03 and a beta of 0.37.

Innoviva (NASDAQ:INVA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter. Innoviva had a positive return on equity of 15.77% and a negative net margin of 16.15%. The business had revenue of $88.63 million during the quarter.

Institutional Trading of Innoviva

A number of hedge funds and other institutional investors have recently modified their holdings of INVA. Martingale Asset Management L P raised its position in shares of Innoviva by 0.7% during the first quarter. Martingale Asset Management L P now owns 78,412 shares of the biotechnology company's stock worth $1,422,000 after purchasing an additional 570 shares during the period. BOKF NA raised its position in shares of Innoviva by 2.3% during the fourth quarter. BOKF NA now owns 28,648 shares of the biotechnology company's stock worth $495,000 after purchasing an additional 641 shares during the period. Farther Finance Advisors LLC raised its position in shares of Innoviva by 10.3% during the first quarter. Farther Finance Advisors LLC now owns 8,516 shares of the biotechnology company's stock worth $153,000 after purchasing an additional 795 shares during the period. Parallel Advisors LLC raised its position in Innoviva by 157.5% during the second quarter. Parallel Advisors LLC now owns 1,849 shares of the biotechnology company's stock valued at $37,000 after buying an additional 1,131 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Innoviva by 3.8% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,490 shares of the biotechnology company's stock valued at $546,000 after buying an additional 1,162 shares during the period. Institutional investors own 99.12% of the company's stock.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.